TRIM33 and dermatomyositis: From an immunological perspective, the autoantibodies implicated in DM, especially those targeting nuclear proteins (such as TIF1γ or NXP2), could participate directly in pathological processes through the recognition of tumor neoantigens, molecular mimicry, or the disruption of immunological tolerance.